Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) disclosed that its Chief Financial Officer, Executive Vice President, Treasurer, and director, William J. Peters, sold 11,000 shares of common stock on November 16, 2026, for a total of $329,890. The shares were sold at $29.99 each, a price slightly above the stock's current level of $28.25. The transaction was executed under a Rule 10b5-1 trading plan that Peters adopted on March 10, 2026.
The sale comes after a notable six-month rally in which Amphastar's shares climbed more than 53%. Despite that advance, an analysis of the stock's Fair Value suggests it remains undervalued. The pre-arranged nature of the plan means the sale was scheduled in advance and is not necessarily indicative of Peters' current view of the company.
On the same day, Peters also acquired 11,000 shares of Amphastar common stock through the exercise of employee stock options. Those shares were acquired at an exercise price of $17.99 per share, for a total of $197,889. The options were fully vested and immediately exercisable, according to the disclosure.
Following these transactions, Peters directly holds 167,076 shares of Amphastar Pharmaceuticals common stock. The combined moves - selling shares at $29.99 and exercising options at $17.99 - resulted in a net gain before taxes and other costs, though the disclosure does not specify any tax withholding or other fees.
The insider activity coincides with a period of strong operational performance at Amphastar. In its most recent quarter, the company reported record third-quarter 2026 revenue of $207.6 million, surpassing Wall Street expectations. Adjusted earnings per share reached $1.14, exceeding analyst projections of $0.86 by 32.6%. The strong results were driven by increased sales of key branded products, including BAQSIMI and Primatene MIST, both of which achieved record quarterly sales.
However, the company's gross margin decreased to 48% from 51% a year earlier. The decline was attributed to pricing pressures and costs associated with FDA-related remediation at its IMS manufacturing facility. Despite these challenges, Amphastar's board authorized an additional $50 million for share repurchases, a move that reflects confidence in the company's financial position.
Revenue for the quarter rose 8% from the previous year and 13% from the second quarter, highlighting robust commercial execution. Newer product launches, such as ipratropium bromide and teriparatide, also contributed to the revenue growth. These developments underscore Amphastar's ability to navigate operational headwinds while achieving record sales.
The stock closed at $28.25, up $0.14 or 0.50%, on the day of the disclosure. In after-hours trading, shares edged up $0.01 to $28.26. The disclosure of the insider transactions provides investors with additional data points on executive activity at the company.